MEDCO FORUM®

PRESENTING INNOVATIVE PRODUCTS & SERVICES TO HEALTHCARE PROFESSIONALS

VERMILLION
YOUR HEALTH, OUR PASSION

We invite you to join us for an evening Symposium at AAGL

November 17-21, 2014
VANCOUVER, British Columbia

43rd AAGL
GLOBAL CONGRESS
ON MINIMALLY INVASIVE GYNECOLOGY

The Prediction of Malignancy before Surgery
A Review of OVA1 for Ovarian Mass Risk Stratification

Course Description: Currently, gynecologic surgeons and health institutions alike are wrestling with laparoscopic, uterine power morcellation. At the heart of this dilemma is the prediction of malignancy before the index surgery. While there is not a reliable preoperative tool for the diagnosis of the leiomyoma before surgery, the diagnostic tool OVA1 does exist for preoperative assessment of the most deadly of gynecologic malignancies, ovarian cancer.

Wednesday, November 19th, 2014
5:05PM – 7:05PM
Vancouver Convention Center, Room 211

Faculty:

Judith Wolf, M.D.
Gynecologic Oncologist
Chief Medical Officer, Vermillion

Hector O. Chapa, M.D., F.A.C.O.G.
Medical Director, Women's Specialty Center Dallas
Methodist Medical Center, Dallas, Clinical Faculty

RSVP by November 10th to Meghan Goertz: mgoertz@vermillion.com

Please come visit Vermillion at Booth Number 719

OVA1 | ova-1.com
12117 Bee Caves Rd
Building III, Suite 100
Austin, TX 78738

info@ova-1.com
(844) 277.4721
Fax: (512) 439.2038